Corcept Therapeutics Company Insiders

Corcept Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of 0.13 % which means that it generated a profit of $0.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2577 %, meaning that it created $0.2577 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.16 in 2025. Return On Capital Employed is likely to gain to 0.20 in 2025. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 750.5 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 349.7 K in 2025. Net Income Applicable To Common Shares is likely to gain to about 122.3 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 83.1 M in 2025.

Corcept Therapeutics Workforce Comparison

Corcept Therapeutics Profit Margins

The company has Profit Margin (PM) of 0.23 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26.

Corcept Therapeutics Insider Trading History

Corcept Therapeutics Notable Stakeholders

The success or failure of an entity such as Corcept Therapeutics often depends on how effective the management is. Corcept Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Corcept management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Corcept management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Corcept Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Corcept Therapeutics Incorporated. Check Corcept Therapeutics' Beneish M Score to see the likelihood of Corcept Therapeutics' management manipulating its earnings.

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.